Tacrolimus versus cyclosporin in renal transplantation in Italy: cost-minimisation and cost-effectiveness analyses.

Abstract

In the first 6 months after renal transplantation, tacrolimus-based therapy was less costly than cyclosporin-ME based therapy. When surviving patients with a rejection-free graft were considered, tacrolimus was the dominant therapy.